VG2025 treatment for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called VG2025 to treat advanced intrahepatic cholangiocarcinoma, a type of cancer that starts in the bile ducts inside the liver. The study aims to see if VG2025 is safe and effective at slowing or stopping this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have been diagnosed with advanced intrahepatic cholangiocarcinoma (confirmed by biopsy or tissue sample)
- You are willing to use reliable birth control during the trial and for 90 days after treatment ends
- You have not participated in another drug trial within the past 4 weeks
- You have not had major surgery or serious injury in the past 4 weeks
- You do not have active herpes simplex virus infection or other uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new kind of gene therapy (called HNF4α srRNA) given through a vein for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that has stopped responding to standard chemotherapy. The goal is to see if it is safe and if it can help slow or stop the cancer.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This study tests a new treatment combination for advanced bile duct or gallbladder cancer that has not been treated before. It aims to slow cancer growth and may be a good option if you have not had prior therapy for your cancer.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.